Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Why does depression worsen progression and treatment response in the most freque...
Journal Information
Vol. 35. Issue 5.
Pages 338-340 (June 2020)
Vol. 35. Issue 5.
Pages 338-340 (June 2020)
Letter to the Editor
Open Access
Why does depression worsen progression and treatment response in the most frequent neurological disorders? Implications for clinical practice
¿Por qué la depresión empeora el curso y la respuesta al tratamiento en los trastornos neurológicos más frecuentes? Implicaciones en la práctica clínica
Visits
1512
A. Alcántara Monteroa,
Corresponding author
a.alcantara.montero@hotmail.com

Corresponding author.
, C.I. Sánchez Carnererob
a Unidad del Dolor, Hospital Don Benito-Villanueva de la Serena, Don Benito, Badajoz, Spain
b Complejo Hospitalario Universitario de Cáceres, Hospital San Pedro de Alcántara, Cáceres, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor:

It was with great interest that we read the recently published study by Robles Bayón and Gude Sampedro1 on the prevalence of behavioural and psychiatric symptoms, particularly anxiety and depression, in patients from a cognitive neurology clinic. Approximately one in every 2 to 3 patients with the most frequent neurological disorders presents depression at some point over the course of the disease.2 However, numerous studies suggest that depression may also precede neurological disease and even affect its progression, including the response to pharmacological treatment.

In the case of epilepsy, 3 population studies have shown that patients with primary depression are 2 to 7 times more likely to develop epilepsy, and that those with epilepsy are 3 to 5 times more likely to develop depression.3 Likewise, presenting depression (alone or combined with other psychiatric disorders) before epilepsy onset influences disease severity and treatment: patients with depression are twice as likely to develop drug-resistant epilepsy,4 and are at greater risk of presenting seizures at one year5; they even show poorer response to surgical treatment for refractory temporal lobe epilepsy.6

High depression scores may be expected in patients with migraine, although an inverse correlation has also been observed. In a cohort study including nearly 1200 patients with migraine, patients with severe headache, and controls, presence of major depression during a 2-year follow-up period predicted the first-onset migraine (OR=3.4; 95% CI, 1.4-8.7), but not other types of headache.7

Regarding cerebrovascular accidents, a meta-analysis of 28 prospective studies of a total of 320000 individuals, including 8478 patients with stroke, showed that a history of depression was associated with increased risk of stroke (adjusted hazard ratio [HR]=1.45; 95% CI, 1.29-1.63).8

A similar bidirectional relationship has also been observed in dementia. In a meta-analysis of 20 studies including approximately 100000 individuals, 19 studies reported increased risk of Alzheimer disease among individuals with a history of depression; the risk also increased in patients with history of chronic depression.9 However, depression is not simply a premonitory symptom of neurological disease; as with stroke, the association between depression and dementia has been linked to greater difficulties with the activities of daily living, more severe cognitive impairment, and earlier institutionalisation.10

History of depression also triples the risk of developing Parkinson's disease, according to a retrospective cohort study evaluating over 68000 patients in the Netherlands.11 Furthermore, presence of depression in patients diagnosed with Parkinson's disease has been associated with cognitive impairment at different levels and with poorer motor function.12

The trends discussed above suggest that neurological diseases may share a number of pathogenic mechanisms with mood disorders, which may present when several factors are met.

In the case of the association between depression and epilepsy, the hypothesis of a common pathogenic mechanism may be explained as follows: when a person with depression presents another pathogenic factor (e.g., head trauma or genetic predisposition), the epileptogenic process will encounter a damaged brain. This may explain why these patients are more likely to develop refractory epilepsy. Furthermore, studies in animals and in patients with epilepsy have shown a neurochemical link between both types of disorders. For example, patients with temporal lobe epilepsy and those with major depression have shown similarly reduced serotonin 5-HT1A receptor binding in the hippocampus and other brain structures.13 Another potential link between depression and epilepsy is the high concentration of glutamate seen in the plasma, CSF, and cerebral cortex of patients with depression; increased glutamatergic tone plays an essential role in the development of epileptic foci.14

Other studies suggest common neuropathological manifestations. In a 2010 study conducted in Brazil, which evaluated 48 patients with refractory mesial temporal lobe epilepsy, the 24 patients with concomitant depression showed more marked grey matter volume loss.15

Depression not only affects these patients’ quality of life but can also modify the progression and severity of neurological disease. Neurological symptoms increase the risk of presenting psychiatric disorders, and the opposite may also occur.

The consequences of these findings are of great significance. If we do not screen for history of depression (the most frequent comorbidity) in patients with epilepsy, Parkinson's disease, or dementia, our evaluation would be incomplete and we would lack important data for choosing the most appropriate drug treatment. Certain antiepileptic drugs (levetiracetam, topiramate, vigabatrin, etc.) should be considered the third or fourth line of treatment in patients with depression; the same is true for Parkinson's disease. If we disregard the impact of history of depression on the progression of motor symptoms, how can we be certain that a lack of response is due to ineffectiveness of the drug?

In conclusion, depression may constitute an aspect of the neurological disease rather than an independent sign; its impact on patients’ quality of life is such that it should become a treatment priority in neurological patients. However, the million-dollar question is whether effective management of depression can prevent or modify the progression of neurological disease. Although the available evidence suggests that it may, further research is needed. While we await more conclusive evidence, the psychiatric component of neurological disease should always be evaluated.

References
[1]
A. Robles Bayón, F. Gude Sampedro.
Síntomas conductuales y psiquiátricos en neurología cognitiva.
Neurologia, 32 (2017), pp. 81-91
[2]
A.M. Kanner.
Psychiatric comorbidities in epilepsy: should they be considered in the classification of epileptic disorders?.
Epilepsy Behav, 64 (2016), pp. 306-308
[3]
A.M. Kanner.
Psychopathology and epilepsy: is it the chicken or the egg?.
Epilepsy Curr, 6 (2006), pp. 147-149
[4]
N. Hitiris, R. Mohanraj, J. Norrie, G.J. Sills, M.J. Brodie.
Predictors of pharmacoresistant epilepsy.
Epilepsy Res, 75 (2007), pp. 192-196
[5]
S. Petrovski, C.E. Szoeke, N.C. Jones, M.R. Salzberg, L.J. Sheffield, R.M. Huggins, et al.
Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients.
Neurology, 75 (2010), pp. 1015-1021
[6]
G.M. de Araújo Filho, F.L. Gomes, L. Mazetto, M.M. Marinho, I.M. Tavares, L.O. Caboclo, et al.
Major depressive disorder as a predictor of a worse seizure outcome one year after surgery in patients with temporal lobe epilepsy and mesial temporal sclerosis.
[7]
N. Breslau, R.B. Lipton, W.F. Stewart, L.R. Schultz, K.M. Welch.
Comorbidity of migraine and depression: investigating potential etiology and prognosis.
[8]
A. Pan, Q. Sun, O.I. Okereke, K.M. Rexrode, F.B. Hu.
Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review.
JAMA, 306 (2011), pp. 1241-1249
[9]
R.L. Ownby, E. Crocco, A. Acevedo, V. John, D. Loewenstein.
Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.
Arch Gen Psychiatry, 63 (2006), pp. 530-538
[10]
C.G. Lyketsos, C. Steele, L. Baker, E. Galik, S. Kopunek, M. Steinberg, et al.
Major and minor depression in Alzheimer's disease: prevalence and impact.
J Neuropsychiatry Clin Neurosci, 9 (1997), pp. 556-561
[11]
A.G. Schuurman, M. van den Akker, K.T. Ensinck, J.F. Metsemakers, J.A. Knottnerus, A.F. Leentjens.
Increased risk of Parkinson's disease after depression: a retrospective cohort study.
Neurology, 58 (2002), pp. 1501-1504
[12]
S.E. Starkstein, H.S. Mayberg, R. Leiguarda, T.J. Preziosi, R.G. Robinson.
A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease.
J Neurol Neurosurg Psychiatry, 55 (1992), pp. 377-382
[13]
I. Savic, P. Lindström, B. Gulyás, C. Halldin, B. Andrée, L. Farde.
Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy.
[14]
K. Hashimoto.
The role of glutamate on the action of antidepressants.
Prog Neuropsychopharmacol Biol Psychiatry, 35 (2011), pp. 1558-1568
[15]
P.C. Salgado, C.L. Yasuda, F. Cendes.
Neuroimaging changes in mesial temporal lobe epilepsy are magnified in the presence of depression.
Epilepsy Behav, 19 (2010), pp. 422-427

Please cite this article as: Alcántara Montero A, Sánchez Carnerero CI. ¿Por qué la depresión empeora el curso y la respuesta al tratamiento en los trastornos neurológicos más frecuentes? Implicaciones en la práctica clínica. Neurología. 2020;35:338–340.

Copyright © 2018. Sociedad Española de Neurología
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.nrleng.2020.02.006
No mostrar más